Omega-3 fatty acid ethyl esters (Omacor^®) for the treatment of hypertriglyceridemia

ISSN： 1746-0875

Source： Future Lipidology, Vol.2, Iss.3, 2007-06, pp. : 263-270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Omacor® (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia

By Rupp Heinz

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 675-690

Springer Publishing Company

Access to resources Recommend Favorite

Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids

By Brunton Stephen Collins Nancy

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1139-1145

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters

By Halcox Julian P

Clinical Lipidology, Vol. 8, Iss. 3, 2013-06 ,pp. : 329-344

Future Medicine

Access to resources Recommend Favorite

A Short History of Fatty Acid Ethyl Esters

ALCOHOLISM (ELECTRONIC), Vol. 39, Iss. 3, 2015-03 ,pp. : 413-415

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients

By Bays Harold E. Maki Kevin C. McKenney James Snipes Rose Meadowcroft Amy Schroyer Rosemary Doyle Ralph T. Stein Evan

Current Medical Research and Opinion, Vol. 26, Iss. 4, 2010-04 ,pp. : 907-915

Informa Healthcare

Access to resources Recommend Favorite